ESR1 and breast cancer: Despite the use of adjuvant endocrine therapy with tamoxifen and aromatase inhibitors (AIs), 20% of patients with newly diagnosed early-stage estrogen receptor-positive (ER+) breast cancer (BC) will relapse within 10 years of diagnosis and additional relapse risk continues for the duration of a patient’s lifetime1.